Repros Gains as Androxal Meets Testosterone Study Goals

Recommended by Dr. Michael White, Updated on January 5th, 2018

Repros Therapeutics Inc., (RPRX) maker of an experimental drug to restore normal testosterone levels to men with hypogonadism, gained the most in more than two years after the drug met study goals.

Repros soared 76 percent to $16.10 at the close in New York, for the biggest one-day increase since December 2010. The shares of the Woodlands, Texas-based company have almost quadrupled in the past 12 months.

The medicine, Androxal, is designed to treat men with secondary hypogonadism, a condition characterized by low levels of the hormone testosterone caused by a problem in the hypothalamus or pituitary gland, according to the Mayo Clinic. The 151-patient study showed that 79 percent of men treated with Androxal reached a 24-hour average testosterone level in the normal range, the company said today in a statement, meeting the studys main goal.

Androxal also was shown to be generally well-tolerated and met a non-inferiority goal in sperm count compared with placebo, the company said in the statement.

To contact the reporter on this story: Meg Tirrell in New York at mtirrell@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Read this article:

Repros Gains as Androxal Meets Testosterone Study Goals

Contact Us Now

Your Name (*)
Your Email (*)
Your Phone (*)
Select A Program
Select Your US State (*)
Select your age (30+ only)
Confirm over 30 years old (*) Yes
Confirm United States Resident? (*) Yes
(*) - Required
After completing the contact form above, press the submit button. We will send you a confirmation email. Please check your email. For security purposes, please give us a call at 1-800-469-3343 if you don't receive an email.

Related Post

Word Count: 198

Comments are closed.


low specialist and symptoms levels of testosterone signs

treatment of low testosterone levels

what causes low testosterone levels in men